{"schema_version":"secwatch.filing_event.v1","accession":"0001630627-26-000010","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2026-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.619573+00:00","generated_at":"2026-05-15T06:47:39.001818+00:00","sec_items":["2.02","7.01","5.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Treace prelim Q1 rev $47.0-47.2M; FY26 guidance raised to $202-212M; CCO departs","bullets":["Preliminary Q1 revenue expected $47.0-47.2M; cash $51.9M, up $3.5M from Dec 2025.","Full-year 2026 revenue guidance updated to $202-212M vs prior $200-212M.","Chief Commercial Officer Gaetano Guglielmino departed April 8; role not replaced.","CCO to consult through Jan 2027; $36,667/month fee, COBRA, prorated bonus, equity vest.","SVP Sales will now report directly to CEO John Treace."],"urls":{"canonical":"https://secwatch.observer/filing/0001630627-26-000010","json":"https://secwatch.observer/filing/0001630627-26-000010.json","markdown":"https://secwatch.observer/filing/0001630627-26-000010.md","text":"https://secwatch.observer/filing/0001630627-26-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000163062726000010/0001630627-26-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000163062726000010/tmci-20260408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:47:39.001818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}